Drug firms Pfizer and Flynn Pharma have been fined nearly £90m (€105.6m) for "excessive and unfair" pricing to Britain's National Health Service after hiking the cost of an anti-epilepsy drug by up to 2,600% overnight.
The Competition and Markets Authority said drug maker Pfizer and distributor Flynn Pharma broke competition law when they increased the cost of a medicine used by around 48,000 patients in the UK.
The watchdog said their moves saw the cost to the NHS of phenytoin sodium capsules rocket from around £2m a year in 2012 to about £50m in 2013 - far more than Pfizer was charging in any other European country.
Pfizer was handed a record £84.2m fine, while Flynn Pharma was fined £5.2m.
The CMA has also ordered both firms to reduce their prices for the anti-epilepsy drug.